

12.02.2020

To, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001

Scrip Code: 540108

Scrip Symbol: TAHL

Sub: Outcome of Board Meeting held on 12th February, 2020

Dear Sir,

The Board of Directors of the Company at its meeting held on Wednesday, 12<sup>th</sup> February, 2020 inter alia has transacted, adopted and approved the following:

The Standalone Un-audited Financial Results for the Quarter and Nine Months ended on 31<sup>st</sup>
 December, 2019 as per Regulation 33 of SEBI (LODR) Regulation, 2015 with Limited Review Report of Statutory Auditors of the Company.

The Meeting of Board of Directors of the Company commenced from 15:45 and closed at 17:30.

Kindly take note of the above and oblige.

By order of the Board

For Tiaan Ayurvedic & Herbs Limited

Shando Mathew Company Secretary

## Tiaan Ayurvedic & Herbs Ltd (CIN: L85100GJ1992PLC017397)

Particulars	Quarter Ended			Nine Months Ended		For the yea
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from operations	31,225,000	80,409,720	114,583,381	160,480,490	234,959,869	488,616,42
II. Other income	690,280	0.00	230,268	700,983	323,718	326,96
III. Total Revenue (I + II)	31,915,280	80,409,720	114,813,649	161,181,473	235,283,587	488,943,38
IV. Expenses:						100/515/50
Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.0
Purchases of Stock-in-Trade	30,780,272	71,164,651	103,332,284	144,540,584	210,262,420	453,820,510
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	2,741,601	0.00	0.00	2,741,601	0.00	0.00
Employee benefits expense	1,356,300	1,024,620	1,180,845	3,221,629	3,135,595	3,972,475
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expense	539,942	539,942	1,355,384	1,870,399	1,653,922	2,210,899
Other expenses	1,547,670	997,738	1,525,720	3,426,039	3,660,183	5,665,560
Total expenses	36,965,785	73,726,951	107,394,233	155,800,252	218,712,120	465,669,440
V. Profit before exceptional items and tax (III - IV)	(5,050,505)	6,682,769	7,419,416	5,381,221	16,571,467	23,273,949
VI. Exceptional items		0.00	0.00	0.00	0.00	0.00
VII. Profit before exceptional items and tax (V - VI)	(5,050,505)	6,682,769	7,419,416	5,381,221	16,571,467	23,273,949
VIII. Tax expense:	/					25,275,545
(1) Current tax	(1,300,505)	1,737,520	1,619,631	1,374,254	3,968,563	5,818,487
(2) Deferred tax		0.00	0.00	0.00	0.00	0.00
IX. Profit (Loss) for the period from continuing operations (VII-VIII)	(3,750,000)	4,945,249	5,799,785	4,006,967	12,602,904	17,455,462
X. Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
KII. Profit/(loss) from Discontinuing operations (after eax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
KIII. Details of Equity Share Capital			ě.			
Paid-up Equity Share Capital	51,668,000	51,668,000	51,668,000	51,668,000	51,668,000	51,668,000



Face value of equity share capital	10	10	10	10	10	10
XIV. Other Comprehensive Income						
A. (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B. (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) Comprising profit(loss) and other comprehensive Income for the period)	(3,750,000)	4,945,249	5,799,785	4,006,967	12,602,904	17,455,462
XVI. Earnings per equity share:		20		1,000,001		
(1) Basic	(0.73)	0.957	1.122	0.78	2.44	3.378
(2) Diluted	(0.73)	0.957	1.122	0.78	2.44	3.378

## Notes:

- The Standalone Un-Audited Financial Results of the Company for the Quarter and Nine Months ended on 31<sup>st</sup>
  December, 2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their
  meeting held on 12.02.2020
- The Limited Review of Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2019 as required in terms of Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015 has been carried out by Statutory Auditors.
- 3. Previous year/period figures have been regrouped/rearranged wherever necessary to make them Comparable with current period figures.
- 4. The Company has only One Reportable Segment i.e. Ayurvedic & Herbs Products.

Date: 12.02.2020 Place: Vadodara For Tiaan Ayurvedic & Herbs Ltd

Rangarajan Sudharshan Managing Director





Review report to

## The Board of Directors of Tiaan Ayurvedic & Herbs Limited

We have reviewed the accompanying statement of unaudited financial results of Tiaan Ayurvedic & Herbs Limited for the period Quarter and Nine Months ended 31st December, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MEHUL M SHAH& CO.

CHARTERED ACCONTNATS

FRN.141907W

(MEHUL SHAP

M. No.044044

UDIN: 20044044AAAAAAK5547

Date: 12.02.2020 Place: Mumbai